Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 4/20 | 0.45 |
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.34 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.34 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.34 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.34 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711346 | 0.91 | MEN1 (0.44) | TSHRHPGDMEN1MAPK1KMT2A | |
| SCHEMBL6712739 | 0.91 | ALDH1A1 (0.40) | TSHRHPGDMEN1MAPK1KMT2A | |
| SCHEMBL6712599 | 0.90 | CES2 (0.46) | TSHRHPGDMEN1MAPK1KMT2A | |
| SCHEMBL6712717 | 0.80 | ALDH1A1 (0.40) | TSHRHPGDMEN1MAPK1KMT2A | |
| SCHEMBL6711516 | 0.80 | MAPK14 (0.43) | CES2CES1POLB | |
| SCHEMBL6709920 | 0.78 | MAPK14 (0.40) | CES2CES1RAB9AMRGPRX1 | |
| SCHEMBL6710179 | 0.77 | ALDH1A1 (0.44) | TSHRMEN1KMT2ANPSR1CES2 | |
| SCHEMBL27673772 | 0.76 | CES2 (0.74) | TSHRHPGDMEN1MAPK1KMT2A | |
| SCHEMBL27241209 | 0.72 | MRGPRX1 (0.36) | TSHRMEN1KMT2ANPSR1MAPT | |
| SCHEMBL6716730 | 0.72 | CYP11B2 (0.38) | MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | N.V. ORGANON (NL) | 2004-11-18 | — | — | US | disclosed |
| EP-0898566-B1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL NV (NL) | 2002-11-06 | — | — | EP | disclosed |
| US-20020037885-A1 | Therapeutic compounds | DIJCKS FREDERICUS ANTONIUS (NL) | 2002-03-28 | — | — | US | disclosed |
| US-6313139-B1 | ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS | AKZO NOBEL N. V. (NL) | 2001-11-06 | — | — | US | disclosed |
| US-6080773-A | USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS | AKZO NOBEL, N.V. (NL) | 2000-06-27 | — | — | US | disclosed |
| EP-0898566-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | Akzo Nobel N.V. (NL) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040027-A1 | SUBSTITUTED BENZYLAMINES AND THEIR USE FOR THE TREATMENT OF DEPRESSION | AKZO NOBEL N.V. (NL) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229910-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | TSHR 2499/4885HPGD 548/4885MEN1 3408/4885 |
| US-20020037885-A1 | Therapeutic compounds | BDNF, PNMT, SLC18A2 | TSHR 2499/4885HPGD 548/4885MEN1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.